Search

Your search keyword '"Prince, Henry Miles"' showing total 34 results
Start Over Author "Prince, Henry Miles"
34 results on '"Prince, Henry Miles"'

1. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

Author

Han, Jessy Xinyi, Koh, Min Jung, Boussi, Leora, Sorial, Mark, McCabe, Sean M., Peng, Luke, Singh, Shambhavi, Eche-Ugwu, Ijeoma Julie, Gabler, Judith, Fernandez Turizo, Maria J., MacVicar, Caroline T., Garg, Aditya, Disciullo, Alexander, Chopra, Kusha, Lenart, Alexandra, Nwodo, Emmanuel, Barnes, Jeffrey, Koh, Min Ji, Miranda, Eliana, Chiattone, Carlos, Stuver, Robert, Horwitz, Steven M., Merrill, Mwanasha, Jacobsen, Eric, Manni, Martina, Civallero, Monica, Skrypets, Tetiana, Lymboussaki, Athina, Federico, Massimo, Kim, Yuri, Kim, Jin Seok, Cho, Jae Yong, Eipe, Thomas, Shet, Tanuja, Sridhar, Epari, Shetty, Alok, Saha, Saswata, Jain, Hasmukh, Sengar, Manju, Van Der Weyden, Carrie, Prince, Henry Miles, Hamouche, Ramzi, Murdashvili, Tinatin, Foss, Francine, Gentilini, Marianna, Casadei, Beatrice, Zinzani, Pier Luigi, Okatani, Takeshi, Yoshida, Noriaki, Yoon, Sang Eun, Kim, Won-Seog, Panchoo, Girisha, Mohamed, Zainab, Verburgh, Estelle, Alturas, Jackielyn Cuenca, Al-Mansour, Mubarak, Ford, Josie, Cabrera, Maria Elena, Ku, Amy, Bhagat, Govind, Ma, Helen, Sawas, Ahmed, Kariya, Khyati Maulik, Iwasaki, Makoto, Bhanushali, Forum, O’Connor, Owen A., Marchi, Enrica, Shen, Changyu, Shah, Devavrat, and Jain, Salvia

Published
2024
Full Text
View/download PDF

2. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies

Author

Campbell, Ashlea, primary, Teh, Benjamin, additional, Mulligan, Stephen, additional, Ross, David M., additional, Weinkove, Robert, additional, Gilroy, Nicole, additional, Gangatharan, Shane, additional, Prince, Henry Miles, additional, Szer, Jeff, additional, Trotman, Judith, additional, Lane, Steven, additional, Dickinson, Michael, additional, Quach, Hang, additional, Enjeti, Anoop K., additional, Ku, Matthew, additional, Gregory, Gareth, additional, Hapgood, Gregory, additional, Ho, Phoebe Joy, additional, Cochrane, Tara, additional, Cheah, Chan, additional, Greenwood, Matthew, additional, Latimer, Maya, additional, Berkahn, Leanne, additional, Wight, Joel, additional, Armytage, Tasman, additional, Diamond, Peter, additional, Tam, Constantine S., additional, and Hamad, Nada, additional

Published
2023
Full Text
View/download PDF

3. 1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma

Author

Tan, Peter, primary, Shavaksha, Sorab Jehangir, additional, Prince, Henry Miles, additional, Yin, Qingsong, additional, Li, Chunrui, additional, Cai, Zhen, additional, Bao, Li, additional, Jing, Hongmei, additional, Lai, Peilong, additional, Deng, Qiumei, additional, Zhang, Mingfei, additional, Zeng, Shuqi, additional, Lu, Qiaoyang, additional, Jiang, Chengjun, additional, Ren, Fang, additional, Wu, Danqing, additional, and Mi, Jianqing, additional

Published
2023
Full Text
View/download PDF

4. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies.

Author

Campbell, Ashlea, Teh, Benjamin, Mulligan, Stephen, Ross, David M., Weinkove, Robert, Gilroy, Nicole, Gangatharan, Shane, Prince, Henry Miles, Szer, Jeff, Trotman, Judith, Lane, Steven, Dickinson, Michael, Quach, Hang, Enjeti, Anoop K., Ku, Matthew, Gregory, Gareth, Hapgood, Gregory, Ho, Phoebe Joy, Cochrane, Tara, and Cheah, Chan

Subjects
THERAPEUTIC use of monoclonal antibodies, EVALUATION of medical care, DRUG efficacy, COVID-19, COMMUNICABLE diseases, HEMATOLOGY, COVID-19 vaccines, ANTIVIRAL agents, CANCER patients, PREVENTIVE health services, SEVERITY of illness index, MEDICAL protocols, VACCINE effectiveness, PRE-exposure prophylaxis, PATIENT monitoring, HEMATOLOGIC malignancies, INTERPROFESSIONAL relations, CRITICAL care medicine, DISEASE duration, ISOLATION (Hospital care), DISEASE management, COMORBIDITY, EARLY medical intervention
Abstract

Despite widespread vaccination rates, we are living with high transmission rates of SARS‐CoV‐2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID‐19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B‐cell malignancies and on B‐cell‐targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID‐19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de‐isolation following COVID‐19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID‐19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID‐19 Guidelines. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study

Author

Odutola, Michael K., primary, van Leeuwen, Marina T., additional, Bassett, Julie K., additional, Bruinsma, Fiona, additional, Turner, Jennifer, additional, Seymour, John F., additional, Prince, Henry Miles, additional, Milliken, Samuel T., additional, Hertzberg, Mark, additional, Roncolato, Fernando, additional, Opat, Stephen S., additional, Lindeman, Robert, additional, Tiley, Campbell, additional, Trotman, Judith, additional, Verner, Emma, additional, Harvey, Michael, additional, Underhill, Craig R., additional, Benke, Geza, additional, Giles, Graham G., additional, and Vajdic, Claire M., additional

Published
2023
Full Text
View/download PDF

7. Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Author

Boussi, Leora S, primary, Koh, Min Jung, additional, Han, Xinyi, additional, Peng, Luke, additional, Koh, Min Ji, additional, Eche, Ijeoma, additional, Ford, Josie Germain, additional, Singh, Shambhavi, additional, Miranda, Eliana, additional, Chiattone, Carlos S., additional, Van Der Weyden, Carrie, additional, Prince, Henry Miles, additional, Foss, Francine M., additional, Yoon, Sang Eun, additional, Kim, Won-Seog, additional, Panchoo, Girisha, additional, Verburgh, Estelle, additional, Cuenca Alturas, Jackielyn, additional, Al-mansour, Mubarak, additional, Manni, Martina, additional, Federico, Massimo, additional, Cabrera, Maria Elena, additional, Casadei, Beatrice, additional, Zinzani, Pier Luigi, additional, Yoshida, Noriaki, additional, Okatani, Takeshi, additional, Merrill, Mwanasha H., additional, Jacobsen, Eric D, additional, O'Connor, Owen A., additional, Marchi, Enrica, additional, and Jain, Salvia, additional

Published
2022
Full Text
View/download PDF

8. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Author

Lee, Hun Ju, primary, Abramson, Jeremy S., additional, Bartlett, Nancy L., additional, Burke, John M., additional, Lynch, Ryan C., additional, Eva, Domingo Domenech, additional, Hess, Brian T., additional, Schuster, Steven R., additional, Linhares, Yuliya, additional, Ramchandren, Rod, additional, Gandhi, Mitul, additional, Mowat, Rex, additional, Shah, Harsh, additional, Rossi, Giuseppe, additional, Hahn, Uwe H, additional, Prince, Henry Miles, additional, Ho, Linda, additional, Guo, Wenchuan, additional, Yasenchak, Christopher A., additional, and Straus, David J., additional

Published
2022
Full Text
View/download PDF

11. A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Author

Rossi, Giuseppe, primary, Prince, Henry Miles, additional, Tam, Constantine S., additional, Ku, Matthew, additional, Thieblemont, Catherine, additional, Popplewell, Leslie L., additional, Wermke, Martin, additional, Haioun, Corinne, additional, Wong Doo, Nicole, additional, Viardot, Andreas, additional, Ferreri, Andrés J M, additional, Ferrari, Silvia, additional, Wong, Hansen L., additional, Kadu, Priti, additional, Zugmaier, Gerhard, additional, Zeng, Yi, additional, and Rambaldi, Alessandro, additional

Published
2021
Full Text
View/download PDF

16. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Author

Bhurani, Mansi, primary, Admojo, Lorenz, additional, Van Der Weyden, Carrie, additional, Twigger, Robert, additional, Bazargan, Ali, additional, Quach, Hang, additional, Zimet, Allan, additional, Coyle, Luke, additional, Lindsay, Julian, additional, Radeski, Dejan, additional, Hawkes, Eliza, additional, Kennedy, Glen, additional, Irving, Ian, additional, Gutta, Naadir, additional, Trotman, Judith, additional, Yeung, James, additional, Dunlop, Lindsay, additional, Hua, Minh, additional, Giri, Pratyush, additional, Yuen, Sam, additional, Panicker, Shyam, additional, Moreton, Susan, additional, Khoo, Liane, additional, Scott, Ashleigh, additional, Kipp, David, additional, McQuillan, Andrew, additional, McCormack, Chris, additional, Dickinson, Michael, additional, and Prince, Henry Miles, additional

Published
2020
Full Text
View/download PDF

18. MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Author

Leleu, Xavier, primary, Beksac, Meral, additional, Chou, Takaaki, additional, Dimopoulos, Meletios, additional, Yoon, Sung-Soo, additional, Prince, Henry Miles, additional, Pour, Ludek, additional, Shelekhova, Tatiana, additional, Chari, Ajai, additional, Khurana, Monica, additional, Obreja, Mihaela, additional, Qi, Ming, additional, Oriol, Albert, additional, and Siegel, David, additional

Published
2020
Full Text
View/download PDF

20. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Author

Di Ciaccio, Pietro, primary, McCaughan, Georgia, additional, Trotman, Judith, additional, Ho, Phoebe Joy, additional, Cheah, Chan Y., additional, Gangatharan, Shane, additional, Wight, Joel, additional, Ku, Matthew, additional, Quach, Hang, additional, Gasiorowski, Robin, additional, Polizzotto, Mark N., additional, Prince, Henry Miles, additional, Mulligan, Stephen, additional, Tam, Constantine S., additional, Gregory, Gareth, additional, Hapgood, Greg, additional, Spencer, Andrew, additional, Dickinson, Michael, additional, Latimer, Maya, additional, Johnston, Anna, additional, Armytage, Tasman, additional, Lee, Cindy, additional, Cochrane, Tara, additional, Berkhahn, Leanne, additional, Weinkove, Robert, additional, Doocey, Richard, additional, Harrison, Simon J., additional, Webber, Nicholas, additional, Lee, Hui‐Peng, additional, Chapman, Scott, additional, Campbell, Belinda A., additional, Gibbs, Simon D. J., additional, and Hamad, Nada, additional

Published
2020
Full Text
View/download PDF

22. Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab.

Author

Wenwen Zhang, Prince, Henry Miles, and Reardon, Katrina

Abstract

Statin-induced immune-mediated necrotising myopathy (IMNM) is a rare but increasingly recognised myositis. Many cases have positive antibodies to 3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR). The current treatment is ceasing the statin, but often immunosuppressive therapy is required as the antibodies persist, causing muscle necrosis. Despite the use of immunosuppressive medications, most commonly prednisolone, methotrexate, plasma exchange and/or intravenous immunoglobulin, some patients do not respond. We report the successful treatment with rituximab therapy for three patients with IMNM with positive anti-HMGCR antibodies. All three patients with statin-induced IMNM were elderly, with a disease history of 7–9 years, and had failed several immunosuppressive agents. They responded well to rituximab (induction and maintenance) therapy. They remain in remission with no symptoms and normal creatine kinase. One patient had normalisation of anti-HMGCR antibody level, and one patient’s antibody level reduced significantly. Rituximab is an effective immunosuppressive treatment for patients with refractory IMNM. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

23. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.

Author

Hapgood, Greg, Stone, Janey M., Zannino, Diana, George, Anup, Marlton, Paula, Prince, Henry Miles, Hui, Chi-Hung, Prosser, Ian, Lewis, Ian D., Bradstock, Kenneth, and Seymour, John F.

Subjects
T-cell lymphoma, HOSPITAL admission & discharge, DOXORUBICIN, VINCRISTINE
Abstract

To improve complete remission (CR) rates by reducing toxicity and enhancing delivery, we created a modified hyper-CVAD/MA regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine) by reducing the cytarabine dose (3 g/m2 to 2 g/m2) and number of cycles (eight to six). We conducted a phase II trial in the pre-rituximab era in the intermediate–high international prognostic index (IPI) (≥2) de novo diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) (ACTRN12605000105640). CR rates were compared with reported IPI-stratified rates. Sixty-three patients (n = 26 PTCL; n = 37 DLBCL) were evaluated; median follow-up of 30 months. CR rates for PTCL and DLBCL patients were 46% and 49%, respectively, similar with reported CR rates with CHOP-like chemotherapy (p =.6). Of the patients, 51 (81%) experienced ≥1 unplanned hospital admission; only 41 (65%) completed six cycles. The cytarabine modifications did not prevent significant toxicity. Modified hyper-CVAD/MA resulted in similar outcomes to CHOP-like chemotherapy in aggressive lymphomas and was associated with significant toxicity. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

24. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium

Author

Han, Jessy Xinyi, Koh, Min Jung, Boussi, Leora, Sorial, Mark, McCabe, Sean M., Peng, Luke, Singh, Shambhavi, Eche-Ugwu, Ijeoma Julie, Gabler, Judith, Fernandez Turizo, Maria J., MacVicar, Caroline T., Garg, Aditya, Disciullo, Alexander, Chopra, Kusha, Lenart, Alexandra, Nwodo, Emmanuel, Barnes, Jeffrey, Koh, Min Ji, Miranda, Eliana, Chiattone, Carlos, Stuver, Robert, Horwitz, Steven M., Merrill, Mwanasha, Jacobsen, Eric, Manni, Martina, Civallero, Monica, Skrypets, Tetiana, Lymboussaki, Athina, Federico, Massimo, Kim, Yuri, Kim, Jin Seok, Cho, Jae Yong, Eipe, Thomas, Shet, Tanuja, Sridhar, Epari, Shetty, Alok, Saha, Saswata, Jain, Hasmukh, Sengar, Manju, Van Der Weyden, Carrie, Prince, Henry Miles, Hamouche, Ramzi, Murdashvili, Tinatin, Foss, Francine, Gentilini, Marianna, Casadei, Beatrice, Zinzani, Pier Luigi, Okatani, Takeshi, Yoshida, Noriaki, Yoon, Sang Eun, Kim, Won-Seog, Panchoo, Girisha, Mohamed, Zainab, Verburgh, Estelle, Alturas, Jackielyn Cuenca, Al-Mansour, Mubarak, Ford, Josie, Cabrera, Maria Elena, Ku, Amy, Bhagat, Govind, Ma, Helen, Sawas, Ahmed, Kariya, Khyati Maulik, Iwasaki, Makoto, Bhanushali, Forum, O’Connor, Owen A., Marchi, Enrica, Shen, Changyu, Shah, Devavrat, and Jain, Salvia

Abstract

⁃PIRT is a novel prognostic model for patients with R/R mature T-cell and NK-cell lymphomas that defined risk groups with differing outcomes.⁃Small molecule inhibitors offer survival advantage relative to chemotherapy in AITL warranting continued investigation in clinical trials.

Published
2024
Full Text
View/download PDF

25. Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Author

Wong Doo, Nicole, primary, Makalic, Enes, additional, Joo, JiHoon E, additional, Vajdic, Claire M, additional, Schmidt, Daniel F, additional, Wong, Ee Ming, additional, Jung, Chol-Hee, additional, Severi, Gianluca, additional, Park, Daniel J, additional, Chung, Jessica, additional, Baglietto, Laura, additional, Prince, Henry Miles, additional, Seymour, John F, additional, Tam, Constantine, additional, Hopper, John L, additional, English, Dallas R, additional, Milne, Roger L, additional, Harrison, Simon J, additional, Southey, Melissa C, additional, and Giles, Graham G, additional

Published
2016
Full Text
View/download PDF

30. IgA nephropathy associated with cutaneous T cell lymphoma

Author

Bajel, Ashish, primary, Yin Lin, Ming, additional, Hill, Prudence A, additional, Goodman, David, additional, McCormack, Chris, additional, Foley, Peter, additional, Davison, Jill, additional, Hönemann, Dirk, additional, Kenealy, Melita, additional, Lade, Stephen, additional, Ryan, Gail, additional, and Prince, Henry Miles, additional

Published
2009
Full Text
View/download PDF

31. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Author

Coiffier, Bertrand, Pro, Barbara, Prince, Henry Miles, Foss, Francine, Sokol, Lubomir, Greenwood, Matthew, Caballero, Dolores, Morschhauser, Franck, Wilhelm, Martin, Pinter-Brown, Lauren, Iyer, Swaminathan Padmanabhan, Shustov, Andrei, Nielsen, Tina, Nichols, Jean, Wolfson, Julie, Balser, Barbara, and Horwitz, Steven

Subjects
LYMPHOMAS, INTRAVENOUS therapy, THERAPEUTICS, SAFETY, T-cell lymphoma
Abstract

Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ⩾ 1 prior systemic therapy and patients with peripheral T-cell lymphoma (PTCL) who have received ⩾ 1 prior therapy. Approval for PTCL was based on results (n = 130; median follow-up, 13.4 months) from the pivotal study of romidepsin for the treatment of relapsed/refractory PTCL. The objective is to present updated data (median follow-up, 22.3 months) and to characterize patients who achieved long-term responses (⩾ 12 months) to romidepsin. Methods Patients with PTCL who relapsed from or were refractory to ⩾ 1 prior systemic therapy received romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days for up to 6 cycles; patients with response or stable disease could continue romidepsin beyond 6 cycles. The primary endpoint was rate of confirmed/unconfirmed complete response (CR/CRu) determined by an Independent Review Committee. Secondary endpoints included objective response rate (ORR) and duration of response (DOR). For patients who achieved CR/CRu, baseline characteristics by DOR (⩾ 12 vs < 12 months) were examined. Results The ORR to romidepsin was 25%, including 15% with CR/CRu. The median DOR for all responders was 28 months (range, < 1-48+) and was not reached for those who achieved CR/CRu. Patients with lack of response or transient response to prior therapy achieved durable responses with romidepsin. Of the 19 patients who achieved CR/CRu, 10 had longterm (⩾ 12 months) responses; none of the baseline characteristics examined-including heavy pretreatment, response to prior therapy, or advanced disease-precluded long-term responses to romidepsin. With a median progression-free survival of 29 months, patients who achieved CR/CRu for ⩾ 12 months had significantly longer survival vs those with CR/CRu for < 12 months or < CR/CRu. Extended treatment and longer follow-up did not affect the reported safety profile of romidepsin. Conclusions Treatment with romidepsin leads to highly durable responses in a subset of patients with relapsed/refractory PTCL, with responses ongoing as long as 48 months. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

32. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Author

Fox, Lucy C., Yannakou, Costas K., Ryland, Georgina, Lade, Stephen, Dickinson, Michael, Campbell, Belinda A., and Prince, Henry Miles

Subjects
B cell receptors, IMMUNOTHERAPY, LYMPH nodes
Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is one of the well-recognized extranodal lymphomas commonly addicted to the B-cell receptor-MYD88 superpathway. We aimed to describe the genomic changes in a patient who progressed through treatment with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. An 80-year-old woman presented with multiply relapsed PCDLBCL-LT after multiple lines of chemoimmunotherapy and radiotherapy. Pre-treatment testing of the localized cutaneous tumor lesion on a lymphoid amplicon panel demonstrated an MYD88 p.L265P mutation. Ibrutinib therapy was subsequently commenced, resulting in complete resolution of the skin disease. Despite an ongoing skin response, the patient developed progressive nodal disease at two months. Genomic analysis of the cutaneous tumor sample at baseline was compared to that of the inguinal lymph node upon progression, and revealed the acquisition of multiple genomic changes. These included several aberrations expected to bypass BTK inhibition, including two CARD11-activating mutations, and a deleterious mutation in the nuclear factor kappa B (NF-κB) negative regulator, NFKBIE. In addition, an IgH-IRF8 translocation was detected (which brings the IRF8 transcription factor under control of the immunoglobulin heavy chain locus), representing a third plausible mechanism contributing to ibrutinib resistance. Several copy-number changes occurred in both samples, including an amplification of 18q, which encodes the anti-apoptotic protein BCL2. We describe the first case of novel genomic changes of PCDLBCL-LT that occurred while on ibrutinib, providing important mechanistic insights into both pathogenesis and drug resistance. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

33. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.

Author

Bhurani M, Admojo L, Van Der Weyden C, Twigger R, Bazargan A, Quach H, Zimet A, Coyle L, Lindsay J, Radeski D, Hawkes E, Kennedy G, Irving I, Gutta N, Trotman J, Yeung J, Dunlop L, Hua M, Giri P, Yuen S, Panicker S, Moreton S, Khoo L, Scott A, Kipp D, McQuillan A, McCormack C, Dickinson M, and Prince HM

Subjects
Aged, Aminopterin analogs & derivatives, Australia epidemiology, Humans, Retrospective Studies, Treatment Outcome, Lymphoma, T-Cell drug therapy, Neoplasm Recurrence, Local drug therapy
Abstract

We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% ( n  = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.

Published
2021
Full Text
View/download PDF

34. Inflammatory Pseudotumor of the Spleen.

Author

Georgia M, Rady K, and Prince HM

Abstract

Isolated splenic inflammatory pseudotumors (IPT) are extremely rare, typically benign, inflammatory lesions with varied clinical presentations that pose a diagnostic challenge to clinicians due to their similarity in appearance to neoplasms. We present the case of a young woman diagnosed with a splenic IPT following investigation for persistent anemia, raised inflammatory markers, and polyclonal hypergammaglobulinemia, whose symptoms resolved completely following splenectomy. This case highlights the need to consider this diagnosis when evaluating patients with a splenic mass of unknown etiology.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results